Last reviewed · How we verify
Xalatan®/DE-130A
Xalatan®/DE-130A is a prostaglandin analogue Small molecule drug developed by Santen SAS. It is currently in Phase 3 development for Glaucoma, Ocular hypertension. Also known as: Catiolanze®.
Xalatan is a prostaglandin analogue that reduces intraocular pressure by increasing uveoscleral outflow.
Xalatan (latanoprost) is used to treat Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease. It is compared to DE-130A in clinical trials for efficacy and safety.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Xalatan®/DE-130A |
|---|---|
| Also known as | Catiolanze® |
| Sponsor | Santen SAS |
| Drug class | prostaglandin analogue |
| Target | FP receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Xalatan works by mimicking the action of a natural prostaglandin, prostaglandin F2α, which is involved in the regulation of intraocular pressure. By increasing uveoscleral outflow, Xalatan reduces the pressure in the eye, thereby reducing the risk of glaucoma progression.
Approved indications
- Glaucoma
- Ocular hypertension
Common side effects
- conjunctival hyperemia
- eye itching
- eye pain
- foreign body sensation in the eye
- diplopia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xalatan®/DE-130A CI brief — competitive landscape report
- Xalatan®/DE-130A updates RSS · CI watch RSS
- Santen SAS portfolio CI
Frequently asked questions about Xalatan®/DE-130A
What is Xalatan®/DE-130A?
How does Xalatan®/DE-130A work?
What is Xalatan®/DE-130A used for?
Who makes Xalatan®/DE-130A?
Is Xalatan®/DE-130A also known as anything else?
What drug class is Xalatan®/DE-130A in?
What development phase is Xalatan®/DE-130A in?
What are the side effects of Xalatan®/DE-130A?
What does Xalatan®/DE-130A target?
Related
- Drug class: All prostaglandin analogue drugs
- Target: All drugs targeting FP receptor
- Manufacturer: Santen SAS — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Glaucoma
- Indication: Drugs for Ocular hypertension
- Also known as: Catiolanze®
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing